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Basal levels of nuclear localized, tyrosine phosphor-
ylated Stat5 are present in healthy human breast ep-
ithelia. In contrast, Stat5 phosphorylation is fre-
quently lost during breast cancer progression, a
finding that correlates with loss of histological differ-
entiation and poor patient prognosis. Identifying the
mechanisms underlying loss of Stat5 phosphoryla-
tion could provide novel targets for breast cancer
therapy. Pervanadate, a general tyrosine phosphatase
inhibitor, revealed marked phosphatase regulation of
Stat5 activity in breast cancer cells. Lentiviral-medi-
ated shRNA allowed specific examination of the reg-
ulatory role of five tyrosine phosphatases (PTP1B,
TC-PTP, SHP1, SHP2, and VHR), previously impli-
cated in Stat5 regulation in various systems. En-
hanced and sustained prolactin-induced Stat5 ty-
rosine phosphorylation was observed in T47D and
MCF7 breast cancer cells selectively in response to
PTP1B depletion. Conversely, PTP1B overexpression
suppressed prolactin-induced Stat5 tyrosine phosphor-
ylation. Furthermore, PTP1B knockdown increased
Stat5 reporter gene activity. Mechanistically, PTP1B sup-
pression of Stat5 phosphorylation was mediated, at
least in part, through inhibitory dephosphorylation of
the Stat5 tyrosine kinase, Jak2. PTP1B knockdown en-
hanced sensitivity of T47D cells to prolactin phosphor-
ylation of Stat5 by reducing the EC50 from 7.2 nmol/L to
2.5 nmol/L. Immunohistochemical analyses of two in-
dependent clinical breast cancer materials revealed sig-
nificant negative correlations between levels of active
Stat5 and PTP1B, but not TC-PTP. Collectively, our data
implicate PTP1B as an important negative regulator of
Stat5 phosphorylation in invasive breast cancer. (Am J
Pathol 2010, 177:2971–2983; DOI: 10.2353/ajpath.2010.090399)
In breast epithelia, the transcription factors Stat5a and
Stat5b (hereafter collectively termed Stat5) mediate prolac-
tin-induced growth and differentiation. During pregnancy
and lactation, the prolactin/Jak2/Stat5 pathway is critical for
lobuloalveolar expansion, maintenance of a terminally dif-
ferentiated epithelium, and the induction of major milk-re-
lated genes such as whey-acidic protein and -casein.1–6
Following tyrosine phosphorylation by the prolactin recep-
tor-associated kinase Jak2, Stat5 translocates to the nu-
cleus and binds target DNA sequences. Outside of preg-
nancy and lactation, a basal level of nuclear localized,
tyrosine phosphorylated Stat5 is present in healthy human
breast epithelia.2 In contrast, Stat5 remains expressed but
is frequently unphosphorylated in human breast cancer, a
finding that is correlated with higher tumor grade, meta-
static progression, and poor clinical outcome.7–10 Further-
more, experimental evidence supports a prodifferentiation
and invasion-suppressive role for prolactin/Jak2/Stat5 sig-
naling in breast cancer.11–13 Therefore, identifying the
mechanisms underlying Stat5 dephosphorylation and po-
tential transcriptional inactivation in breast cancer could
provide novel therapeutic targets for breast cancer therapy.
Several negative regulators of the prolactin/Jak2/Stat5
pathway have been identified. SOCS1, SOCS3, and CIS
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bind Stat5 and decrease activity, block docking sites,
and/or target various proteins in the pathway for protea-
somal degradation.14–18 Caveolin-1 has been reported to
suppress Jak2/Stat5 signaling in mouse mammary epi-
thelia,19 and PIAS3 inhibits Stat5 through sumoylation
and degradation.20–22 However, the absence of Stat5
tyrosine phosphorylation in the presence of continued
Stat5 protein expression in clinical breast cancer speci-
mens suggests that tyrosine phosphatases are important
regulators. In this study we focused on identifying ty-
rosine phosphatases that negatively regulate Stat5 ty-
rosine phosphorylation in human breast cancer.
A recent review noted limitations of previous studies of
phosphatase regulation of prolactin-induced Jak2-Stat5
phosphorylation, most notably that no studies have been
performed in the context of human breast cancer, and the
few studies that used normal mammary epithelial cells
relied exclusively on overexpression methodology.23 To
overcome and resolve these deficiencies we took a can-
didate approach focused on gene knockdown strategies
to specifically identify tyrosine phosphatases that nega-
tively regulate Stat5 phosphorylation in breast cancer.
There are 107 phosphatases in the human proteome capa-
ble of dephosphorylating tyrosine residues.24 Of these, the
classical tyrosine phosphatases PTP1B, TC-PTP, SHP1,
and SHP2 and the dual specificity phosphatase VHR were
chosen for investigation based on their reported regulation
of Stat5 activity in non-breast cells and tissues, modulation
of Jak2/Stat5 homologues signaling in lower organisms, or
ability to regulate Stat5 using in vitro overexpression sys-
tems and phosphatase assays.
There are four Jak and seven Stat genes in mammals
but only one Jak (hop) and one Stat (Stat92E) in Drosoph-
ila.25 Two recent studies using systemic RNAi strategies
screened the Drosophila genome and independently
identified the Drosophila phosphatase Ptp61F as a neg-
ative regulator of hop/Stat92E.26,27 Ptp61F overexpres-
sion can suppress melanotic tumors,27 a finding consis-
tent with the oncogenic role of Stat5 in hematopoietic
malignancies in humans.28–38 There are two mammalian
homologues of Ptp61F, TC-PTP, and PTP1B. Overexpres-
sion studies in Cos7 and the untransformed mouse mam-
mary cell line COMMA-1D indicated that both PTP1B and
TC-PTP suppress prolactin-induced phosphorylation of
Stat5.39,40 In contrast, studies performed using TC-PTP
(/) MEFs or TC-PTP overexpression in the growth
hormone system were unable to show effects on Stat5
tyrosine phosphorylation.41,42 Furthermore, although
PTP1B has been implicated in the regulation of Jak2 in
the growth hormone,42,43 leptin,44–47 and interferon48
pathways, prolactin-induced Jak2 phosphorylation was
not affected by PTP1B in Cos7 or COMMA-1D cells.40
SHP1 has been reported as a likely candidate for
dephosphorylation of growth hormone-activated Stat5.49
SHP1 is commonly inactivated in a majority of leukemia
and lymphomas,50 cancers where Stat5 has a significant
proliferative role.28–38 SHP1 is also expressed in epithe-
lial cells51 and is lost in estrogen receptor (ER)-negative
breast cell lines and in some colorectal cell lines.52,53
SHP2 is a more ubiquitously expressed phosphatase
than SHP1. Substrate trapping mutants have indicated
that SHP2 but not SHP1 interacts with Stat5 in overex-
pression systems.49,54 In vitro tyrosine phosphatase as-
says and indirect immunofluorescence have indicated
the formation of a complex between SHP2 and Stat5.55
Interestingly, SHP2 phosphatase activity was required for
maintaining the activated state of Stat5 as opposed to its
dephosphorylated form. Further evidence that SHP2 pos-
itively regulates the Jak2/Stat5 pathway is based on find-
ings that SHP2 can decrease the amount of SOCS1 me-
diated Jak2 degradation56 and that SHP2 can form a
complex between the GHR and Jak2.57 Consistent with
these findings, SHP2 is also a positive regulator of inter-
feron signaling.58 The dual-specificity phosphatase VHR,
in contrast, was recently implicated as a negative regu-
lator of Stat5 in interferon signaling. VHR acted as part of
a regulatory loop whereby interferon-/-activated Tyk2
phosphorylated and activated VHR, leading to specific
nuclear dephosphorylation of phosphotyrosine-Stat5.59
Based on these variable and inconsistent observations
from overexpression studies, we used gene knockdown
using specific shRNA to query the importance of each of
five candidate phosphatases in enhancing prolactin-in-
duced Jak2-Stat5 phosphorylation in human breast can-
cer cells. Collectively, our data from knockdown studies
in vitro and correlation analyses of clinical breast speci-
mens indicate that dysregulation of PTP1B represents a
major mechanism contributing to the frequent loss of
Stat5 phosphorylation in invasive breast cancer.
Materials and Methods
Antibodies and Reagents
Human prolactin was provided by Dr. A.F. Parlow under
the sponsorship of the National Hormone and Pituitary
Program (Torrance, CA). Monoclonal mouse anti-phos-
photyrosine-Stat5 antibody (AX1) and polyclonal rabbit
anti-Stat5a (AX551) and anti-Stat5b (AX554) were ob-
tained from Advantex BioReagents (Conroe, TX). Mouse
monoclonal pan-Stat5, SHP2, VHR, and anti-mouse and
anti-rabbit horseradish peroxidase-conjugated second-
ary antibodies were purchased from BD Biosciences
(Bedford, MA). Mouse monoclonal Jak2 was purchased
from BioSource (Camarillo, CA). Rabbit polyclonal Jak2
antibody, phosphotyrosine (4G10) mouse monoclonal,
and PTP1B rabbit polyclonal were purchased from Up-
state Biotechnology (Lake Placid, NY). Lamin A/C rabbit
polyclonal antibodies were purchased from Cell Signal-
ing. Rabbit polyclonal calnexin was obtained from Stress-
gen (Ann Arbor, MI). SHP1, PTP1B (PHO2), and TC-PTP
(PHO3–CF4 clone) mousemonoclonal antibodies were pur-
chased fromCalbiochem.Monoclonal mouse anti-Jak2 was
purchased from BioSource. Sodium orthovanadate and
catalase from bovine liver were purchased from Sigma.
Hydrogen peroxide 30% was purchased from Fisher Scien-
tific and the luciferase assay system was purchased from
Promega. Protein A-Sepharose beads were purchased
from Amersham Biosciences.
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Cell Culture
The human breast cancer cell lines T47D and SKBr3
(ATCC, Manassas, VA) were grown in RPMI 1640 me-
dium (Biofluids, Rockville, MD) supplemented with 10%
fetal bovine serum (Atlanta Biologicals, Norcross, GA), 2
mmol/L L-glutamine (GIBCO), and 1 mmol/L sodium pyru-
vate (Cellgro). The human breast cancer cell lines MCF-7
and MDA-MB-231 (ATCC) were grown in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal bo-
vine serum (Atlanta Biologicals). Human breast cancer cell
line ZR-75-1 (ATCC) was grown in Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal bovine serum
(Atlanta Biologicals) and 1 mmol/L sodium pyruvate (Cell-
gro). The stably transfected T47D-CASLUC cell line
(previously described 60) was maintained in RPMI 1640
supplemented with 10% fetal bovine serum (Atlanta Biologi-
cals), 2 mmol/L L-glutamine (GIBCO), 1 mmol/L sodium
pyruvate (Cellgro), and 0.5 g/ml puromycin. The 293FT
cells (Invitrogen) were grown in Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal bovine serum
(Atlanta Biologicals), 2 mmol/L L-glutamine (GIBCO), 1
mmol/L sodium pyruvate (Cellgro), 1X MEM nonessential
amino acids (GIBCO), and 500 g/ml G418.
Whole Cell Lysates, Immunoblots, and
Immunoprecipitations
For whole cell lysates, cells were washed with cold PBS,
lysed in lysis buffer (50 mmol/L Tris pH 7.5, 150 mmol/L
NaCl, 0.1% SDS, 1% Igepal, 0.5% sodium deoxycholate,
2 mmol/L EDTA, 0.01 mol/L sodium phosphate, 50
mmol/L NaF, 2 mmol/L sodium orthovanadate, 1 mmol/L
phenylmethylsulfonylfluoride, 5 g/ml aprotinin, 1 g/ml
pepstatin A, and 2 g/ml leupeptin), collected by scrap-
ing and transferred to Microfuge tubes, and rotated for 1
hour at 4°C end-over-end. Insoluble material was pel-
leted at 13,000  g at 4°C for 30 minutes. Protein con-
centration was determined by the BCA protein assay kit
(Pierce). Standard immunoblot procedures were fol-
lowed. Briefly, 10 or 15 g of total protein was resolved
on a NuPAGE 4 to 12% Bis-Tris gradient gel (Invitrogen).
Proteins were transferred onto a polyvinylidene difluoride
membrane, the membrane was blocked for 1 hour at
ambient temperature with 1% bovine serum albumin, and
subsequently probed with antibody at 4°C overnight. The
membranes were then washed, probed with anti-mouse
secondary antibody, washed, and visualized by chemilumi-
nescence. Phosphotyrosine immunoblots were stripped
and reprobed for total protein expression. For immunopre-
cipitation, clarified whole cell lysates were incubated with
indicated antibodies for 2 hours at 4°C. Antibody-protein
complexes were captured by incubation with Protein A-
Sepharose beads (Amersham Biosciences, Inc., Piscat-
away, NJ) rotating at 4°C for 1 hour and washed three times
in 1 ml of lysis buffer. Immunoprecipitated proteins were
dissolved in 2X loading buffer containing reducing agent,
heated to 70°C for 10 minutes, resolved by SDS-polyacryl-
amide gel electrophoresis, and transferred to polyvinyli-
dene difluoride membranes. Immunoblotting was per-
formed as described above.
Lentivirus Production and Infections
The lentiviral packaging plasmid pCMV-dR8.2 dvpr
(plasmid 8455) and envelope plasmid pCMV-VSV-G
(plasmid 8454) were from Addgene. pLKO.1-puro lenti-
viral vectors containing PTP1B shRNA no. 1 (catalog no.
RHS3979-9571386), PTP1B shRNA no. 2 (catalog no.
RHS3979-9571385), TC-PTP shRNA no. 1 (catalog
no. RHS3979-9571389), TC-PTP shRNA no. 2 (catalog
no. RHS3979-9571387), SHP1 shRNA no. 1 (catalog no.
RHS3979-9575809), SHP1 shRNA no. 2 (catalog
no. RHS3979-9575811), SHP2 shRNA no. 1 (catalog no.
RHS3979-9573790), SHP2 shRNA no. 2 (catalog
no. RHS3979-9573787), VHR shRNA no. 1 (catalog no.
RHS3979-9575758), VHR shRNA no. 2 (catalog
no. RHS3979-9575761), and non-target control shRNA
(catalog no. SHC002) were purchased from Open Bio-
systems. Lentiviral particle production was achieved by
cotransfecting a T175 flask containing 95% confluent
293FT cells (Invitrogen) with 9 g of shRNA lentiviral
plasmid along with 24 g of pCMV-dR8.2 dvpr and 2.4
g of pCMV-VSV-G (a 10:1 ratio). Transfections were
carried out using 108 l of Lipofectamine 2000 (Invitro-
gen), and virus was harvested 48 to 72 hours after trans-
fection. Lentiviral knockdown of indicated proteins was
achieved by infecting 90% confluent cells with lentivirus
overnight in the presence of 8 g/ml Polybrene. The
infection medium was then replaced with fresh growth
medium and cultured for 56 to 72 hours to allow for
efficient protein knockdown. Optimal amount of virus to
treat cells was determined by dose curve and immuno-
blot analysis with subsequent experiments performed us-
ing the lowest amount of virus that gave the maximum
amount of knockdown.
Sodium Orthovanadate Treatment of Cells
A 1-ml solution of 6 mmol/L sodium orthovanadate in PBS
was treated with 6 l of 3% H2O2, vortexed, and incu-
bated for 5 minutes at ambient temperature. Inactivation
of excess H2O2 was accomplished by the addition of
1000 units of catalase from bovine liver for 2 minutes at
ambient temperature. Activated inhibitor was immedi-
ately used to treat cells. Briefly, confluent T47D cells were
serum-starved for 16 hours, then pretreated for 10 min-
utes in fresh serum-free medium with or without 120
mol/L pervanadate followed by stimulation with 10
nmol/L prolactin for 20 minutes in fresh serum-free me-
dium with or without fresh 120 mol/L pervanadate. Pro-
lactin-containing media was washed off and replaced
with fresh serum-free medium with or without fresh 120
mol/L pervanadate, and total cell lysates were collected
at the indicated time points and phosphotyrosine-Stat5
status was monitored by immunoblotting.
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Time Course Experiments
T47D and MCF7 cells were infected with lentivirus ex-
pressing indicated shRNA constructs for 56 hours. Cells
were serum starved overnight, then treated with a pulse
of 10 nmol/L prolactin in fresh serum-free medium for 20
minutes. Prolactin-containing medium was replaced with
fresh serum-free medium and cells were harvested at
time points as indicated using either the whole cell lysate
or cellular fractionation protocols described and ana-
lyzed by immunoblotting. For PTP1B overexpression
studies, 293FT cells were plated in six-well plates and
transfected at 90% confluency with 3.9 g total DNA (1.3
g of pcDNA3-PrlR, 1.3 g of pDNRStat5, and 1.3 g of
pcDNA3.1/Zeo/PTP1B or empty vector control) using
10 l of Lipofectamine 2000 according to the manufac-
turer’s instructions. Fifty-six hours after transfection, cells
were serum-starved for 16 hours, stimulated with 10
nmol/L prolactin for 15 minutes, and cultured in fresh
medium for the indicated times. Cell lysates were ana-
lyzed by immunoblotting as described above and densi-
tometry was conducted from three or four experiments.
Cell Fractionation
Lentiviral-infected, prolactin-stimulated MCF7 cells were
washed with cold PBS twice and then scraped in PBS.
Cells were pelleted at 800 g and resuspended in buffer
A (10 mmol/L HEPES pH 7.9, 10 mmol/L KCl, 0.1 mmol/L
EDTA, 0.4% Igepal, 2 mmol/L sodium orthovanadate, 1
mmol/L phenylmethylsulfonylfluoride, 5 g/ml aprotinin, 1
g/ml pepstatin A, and 2 g/ml leupeptin). Cells were
incubated for 10 minutes on ice, centrifuged at maximum
speed for 3 minutes, and the supernatant was saved as
the cytosolic fraction. The remaining pellet was washed
once with cold PBS and resuspended in buffer B (20
mmol/L HEPES pH 7.9, 200 mmol/L NaCl, 1 mmol/L EDTA,
10% glycerol, 2 mmol/L sodium orthovanadate, 1 mmol/L
phenylmethylsulfonylfluoride, 5 g/ml aprotinin, 1 g/ml
pepstatin A, and 2 g/ml leupeptin). The cell suspension
was shaken vigorously for 2 hours at 4°C, centrifuged at
maximum speed for 5 minutes, and the supernatant saved
as the nuclear fraction. Protein concentrations and immu-
noanalyses were performed as described above.
Luciferase Assays
T47D-CASLUC cells were infected with lentivirus in a
24-well plate, and 72 hours after infection were serum-
starved with or without 10 nmol/L prolactin. After 8 hours
of stimulation the cells were harvested in 1X passive lysis
buffer, and luciferase activity was measured using lucif-
erase reporter assay system (Promega, Madison, WI).
Raw luciferase values (SD) were graphed. Three exper-
iments were performed in triplicate with an extra well of
cells plated for each lentiviral treatment condition to con-
firm effective knockdown. Whole cell lysates were pre-
pared as described above and immunoblot analysis was
performed to determine extent of protein knockdown.
Dose-Response Experiments
Lentiviral-infected T47D cells were serum-starved 56 hours
after infection, serum-starved overnight, and stimulated in
fresh serum-free medium with one of seven different pro-
lactin doses for 15 minutes or left unstimulated as a control.
Densitometry was performed from three experiments, and
EC50 was calculated using SigmaPlot.
Immunohistochemistry
Analyses were performed on a CEMA array containing 48
nonmalignant and 47 malignant breast tissues (material
I). Malignant tissues were represented by ductal carci-
noma in situ (n  3), grade 1 invasive ductal carcinoma
(n  5), grade 2 invasive ductal carcinoma (n  22), and
grade 3 invasive ductal carcinoma (n  17). Among the
invasive ductal carcinomas, 68% were ER-positive, 58%
were progesterone receptor-positive, and 13% were
Her2-positive. The array sections were rehydrated,
heated for 30 minutes in citrate buffer pH 6 (DAKO) in a
microwave for antigen retrieval, blocked with horseradish
peroxidase for 15 minutes, washed, blocked with 10%
goat serum for 30 minutes, and incubated in primary
antibodies to phosphotyrosine-Stat5, PTP1B, or TC-PTP
overnight at 4°C. The array was then washed, treated with
SS Link solution (BioGenex, San Ramon, CA) for 20 min-
utes, washed, treated with SS Label solution (BioGenex)
for 20 minutes, washed, and stained with diaminobenzi-
dine. To complete the protocol the array was counter-
stained with hematoxylin, dehydrated, and mounted with
a coverslip. Staining for PTP1B in nonmalignant and ma-
lignant breast epithelia was generally homogenous, and
pathologists scoring focused on overall staining intensity
instead of Allred score. The stained array was scored by
an independent pathologist as 0, , , , and
statistical analyses were performed using SPSS.
Automated Quantitative Analysis (AQUA)
T47D cells were treated with increasing doses of lentivi-
rus delivering PTP1B shRNA and allowed to culture for 72
hours for efficient knockdown of PTP1B. Cells were fixed,
collected by low-speed centrifugation, and resuspended
in HistoGel for sectioning, fluorescent immunostaining,
and AQUA analysis for detection of PTP1B expression.
Quantitative analysis of PTP1B and phosphotyrosine-
Stat5 expression was performed on a second clinical
material, material II, represented by a CEMA tissue array
containing 100 primary invasive breast carcinoma spec-
imens (grade 1, n  20; grade 2, n  40; grade 3, n 
40). Hormone receptor status as determined by standard
IHC identified 59% ER-positive, 42% progesterone re-
ceptor-positive, and 20% Her2-positive specimens.
Slides were deparaffinized, subjected to low pH antigen
retrieval using the Dako PT module, and stained on a
Dako Autolink Plus autostainer. Endogenous peroxidase
activity was blocked using Dako FLEX peroxidase block
for 10 minutes followed by serum-free protein block for 30
minutes. Slides were incubated for 20 minutes with a
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primary antibody mixture of rabbit anti-phosphotyrosine-
Stat5 (Epitomics 1208-1; 1:1600) and mouse anti-cytok-
eratin (Dako M3515; 1:100), or mouse anti-PTP1B (Cell
Signaling PHO2; 1:400) and rabbit anti-cytokeratin (Dako
Z0622; 1:100), washed three times with Dako wash
buffer, and incubated with relevant secondary antibod-
ies. The secondary antibody cocktail included anti-rabbit
horseradish peroxidase and anti-mouse Alexa Fluor 488
conjugate (Molecular Probes; 1:200) for phosphoty-
rosine-Stat5 staining, or anti-mouse horseradish peroxi-
dase and anti-rabbit Alexa Fluor 488 conjugate (Molec-
ular Probes; 1:200) for PTP1B staining. Following
incubation the slides were washed three times with Dako
wash buffer and incubated with tyramide-Cy5 (Perkin-
Elmer). Finally, all sections were stained with 4,6-dia-
midino-2-phenylindole for nuclear visualization. Auto-
mated quantitative analysis was performed using the
PM2000 imaging platform and AQUA software (HistoRx)
and statistical analysis performed using SPSS.
Results
Prolactin-Induced Tyrosine Phosphorylation of
Stat5 in T47D Cells Is Enhanced and Prolonged
by the Tyrosine Phosphatase Inhibitor
Pervanadate
To broadly assess the involvement of tyrosine phospha-
tases as negative regulators of Stat5 signaling in human
breast cancer cells, we first determined the effect of the
unselective tyrosine phosphatase inhibitor pervanadate.
T47D cells were pretreated with 120 mol/L pervanadate
for 10 minutes, stimulated with prolactin for 20 minutes
followed by the replacement of prolactin-containing me-
dium with pervanadate-containing or control medium,
and monitored over time. Pervanadate treatment did not
affect basal phosphorylation levels of Stat5 but did result in
a markedly enhanced prolactin-induced phosphotyrosine-
Stat5 signal that remained present over the entire 2-hour
time course (Figure 1A). In contrast, control T47D cells not
exposed to pervanadate showed weaker and more tran-
sient phosphotyrosine-Stat5 induction with levels of phos-
photyrosine-Stat5 returning to near baseline by 60 minutes.
These initial data verified that tyrosine phosphatases are
actively involved in negatively regulating prolactin-induced
phosphotyrosine-Stat5 in T47D breast cancer cells.
PTP1B, TC-PTP, SHP1, SHP2, and VHR Are
Expressed in Breast Cancer Cell Lines
Based on studies performed in model systems other than
normal or malignant human breast, we determined
whether five candidate phosphatases implicated in the
regulation of Stat5 activity were expressed in a panel of
human breast cancer cell lines. Figure 1B shows that
PTP1B, TC-PTP, SHP1, SHP2, and VHR are ubiquitously
expressed across the various cell lines but at variable
levels. The lowest level of expression was SHP1 in MDA-
MB-231 cells where SHP1 was detectable in immuno-
blots only after overexposure of film (not shown). Based
on the broad expression of the candidate phosphatases
in T47D cells and its high level of prolactin receptors,
T47D cells were chosen as the primary breast cancer
model cell line for the subsequent experiments.
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Figure 1. Phosphatase inhibition and PTP1B knockdown increased levels of
phosphotyrosine-Stat5 in response to prolactin stimulation. A: Pervanadate
inhibition of Stat5 dephosphorylation. T47D cells treated with or without 120
mol/L pervanadate were analyzed for prolactin-induced Stat5 phosphory-
lation at indicated times by immunoblotting. B: Expression levels of candi-
date phosphatases in whole cell lysates from a panel of five human breast
cancer cell lines. C: Efficacy of two lentiviral-delivered shRNA constructs on
knockdown of PTP1B and TC-PTP compared to lentiviral non-target control
shRNA or uninfected control T47D cells. Batch-to-batch consistency between
lentiviral productions of PTP1B shRNA no.1 was also verified. D: Effect of
PTP1B or TC-PTP knockdown on phosphotyrosine-Stat5. T47D cells were
infected with lentiviral-delivered shRNA against PTP1B, TC-PTP, or a non-
target control, and Stat5 phosphorylation status was measured over time
following a short pulse of prolactin stimulation. E: Densitometry of prolactin-
induced Stat5 phosphorylation following shRNA knockdown of PTP1B or
TC-PTP shRNA in four independent experiments. Vertical bars indicate SEM.
*P  0.03 by analysis of variance. F: Confirmation of prolonged Stat5
phosphorylation following PTP1B knockdown using a second shRNA con-
struct. Prolactin-induced Stat5 tyrosine phosphorylation was measured fol-
lowing lentiviral infection with two independent PTP1B shRNA constructs. G:
Effect of PTP1B overexpression on phosphotyrosine-Stat5. Prolactin receptor
(PrlR), Stat5, and PTP1B were transfected into 293FT cells, and Stat5 phos-
phorylation was analyzed at indicated time points following prolactin pulse.
Arrows indicate time when prolactin (Prl) was removed.
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PTP1B Expression Levels but Not TC-PTP
Resulted in Altered Prolactin-Induced Stat5
Tyrosine Phosphorylation
To delineate the role of the individual tyrosine phospha-
tases in human breast cancer cells, we used lentiviral
delivery of shRNA to individually knock down each of the
five candidate phosphatases. We first focused on the
tyrosine phosphatases PTP1B and TC-PTP because of
the key role of their common homologue, ptp61F, as a
suppressor of the Jak-Stat pathway in Drosophila. The
efficacies of five distinct shRNA constructs for PTP1B or
TC-PTP were first validated (data not shown), and protein
levels of PTP1B or TC-PTP were then evaluated in T47D
cells using the two most effective constructs. Effective
and selective knockdown of both PTP1B and TC-PTP was
achieved (Figure 1C). The effect of knockdown of either
PTP1B or TC-PTP on Stat5 tyrosine phosphorylation lev-
els was then tested using the most efficacious shRNA
construct. T47D cells were stimulated with a 20 minutes
pulse of prolactin 72 hours after lentiviral exposure, fol-
lowed by a change into prolactin-free medium. Whole cell
lysates were collected at predetermined time points and
immunoblotted for phosphotyrosine-Stat5 and total Stat5
protein levels. Phosphotyrosine-Stat5 levels were mark-
edly sustained under conditions of PTP1B knockdown
compared to cells treated with a non-target control
shRNA or mock infection (Figure 1D). In contrast, and
different from observations based on TC-PTP overex-
pression in Cos7 and murine mammary epithelial COMMA-
1D cells,39 TC-PTP knockdown did not affect prolactin-
induced phosphotyrosine-Stat5 levels in T47D breast
cancer cells (Figure 1D). Densitometric analysis of immu-
noblots representing four independent experiments dem-
onstrated that Stat5 phosphorylation was significantly
prolonged following PTP1B depletion, especially notable
at 60 minutes post-prolactin stimulation when compared
to the non-target control (analysis of variance with LSD
post hoc P  0.03), while TC-PTP depletion did not
(Figure 1E). The effect of PTP1B knockdown to prolong
prolactin-induced Stat5 phosphorylation was confirmed
using a second PTP1B shRNA construct (PTP1B shRNA
no. 2) (Figure 1, C and F).
To test whether PTP1B overexpression conversely
would suppress prolactin-induced Stat5 phosphorylation,
we transiently transfected the PrlR, PTP1B, and Stat5 into
293FT cells. Fifty-six hours after transfection the cells
were serum-starved overnight and stimulated with 10
nmol/L prolactin for 15 minutes. The prolactin-containing
medium was washed off, replaced with fresh serum-
containing medium, and lysates were collected at prede-
termined time points. The lysates were immunoblotted for
phosphotyrosine-Stat5, total Stat5, the PrlR, and PTP1B.
PTP1B overexpression markedly suppressed prolactin-
induced tyrosine phosphorylation of Stat5 (Figure 1G).
Attempts to overexpress PTP1B in breast cancer cell
lines T47D, MCF7, and SKBR3 resulted in undetectable
or only low levels of PTP1B overexpression compared to
endogenous levels and did not detectably diminish pro-
lactin-induced Stat5 phosphorylation. Further increasing
PTP1B levels in breast cancer cell lines may have limited
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Figure 2. PTP1B knockdown, but not TC-PTP,
SHP1, SHP2, or VHR, resulted in increased pro-
lactin-induced phosphorylation of the upstream
Stat5 tyrosine kinase, Jak2. A: Immunoblot anal-
ysis of prolactin-induced phosphotyrosine-Jak2
following knockdown of PTP1B or TC-PTP.
T47D cells were infected with lentivirus express-
ing PTP1B or TC-PTP shRNA and stimulated for
20 minutes with 10 nmol/L prolactin, and phos-
photyrosine Jak2 status was analyzed at indi-
cated times following prolactin stimulation. B:
Densitometry of Jak2 phosphorylation following
knockdown of PTP1B or TC-PTP in three exper-
iments. Vertical bars indicate SEM. *P  0.02 by
analysis of variance. C: Immunoblot analysis
demonstrating specific phosphatase knockdown
using lentiviral-delivered shRNA in T47D cells.
D: Effect of additional phosphatases (SHP1,
SHP2, and VHR) on prolactin-induced Jak2
phosphorylation. T47D cells were infected with
SHP1 (D), SHP2 (D), or VHR (E) shRNA and
analyzed by immunoblotting for prolactin-in-
duced Jak2 phosphorylation at the indicated
times following stimulation by prolactin. Ar-
rows indicate time when prolactin (Prl) was
removed.
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efficacy due to tight regulation of already high pre-exist-
ing levels of endogenous PTP1B.
PTP1B Knockdown Modulated Tyrosine
Phosphorylation of the Stat5 Tyrosine Kinase
Jak2
The tyrosine kinase Jak2 has been shown to mediate
prolactin-induced Stat5 phosphorylation in normal and
malignant breast epithelial cells.6,61,62 Despite previous
observations in non-breast cancer cell lines that PTP1B
overexpression did not affect Jak2 phosphorylation,40 we
hypothesized that the increased levels of Stat5 phosphor-
ylation observed in response to PTP1B knockdown in
T47D cells may result from a mechanism related to re-
duced PTP1B inhibition of Jak2, considering Jak2 is au-
tophosphorylated within its catalytic domain on tyrosine
residues 1007 and 1008, which represents a preferred
substrate motif of PTP1B.63 To address this possibility,
additional time course experiments were completed in
T47D cells in which the phosphorylation status of both
Stat5 and Jak2 was monitored following depletion of
PTP1B or TC-PTP. Cells were stimulated for 20 minutes
with prolactin and whole cell lysates were collected at 15
minutes intervals for 60 minutes. In human breast cancer
cells, PTP1B knockdown was associated with marked
enhancement and prolongation of Jak2 tyrosine phos-
phorylation (Figure 2A, upper panels), consistent with
prolongation of downstream Stat5 tyrosine phosphoryla-
tion (Figure 2A, lower panels), while knockdown of TC-
PTP failed to alter Jak2 or Stat5 tyrosine phosphorylation
(Figure 2A). Densitometric analysis of immunoblots from
three experiments indicated that PTP1B knockdown sig-
nificantly enhanced Jak2 phosphorylation following re-
moval of prolactin compared to the non-target control,
especially 30 minutes after prolactin withdrawal (analysis
of variance with LSD post hoc P  0.02), while TC-PTP
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Figure 3. PTP1B knockdown enhanced prolactin-induced phosphoty-
rosine-Stat5 in a second breast cancer cell line, MCF7. A: Immunoblot con-
firmation of specific and effective PTP1B knockdown in MCF7 cells. B:
Efficient fractionation of cytoplasmic and nuclear compartments from repre-
sentative cell lysates using the cytoplasmic endoplasmic reticulum transmem-
brane protein calnexin and the nuclear proteins lamin A and C. C and D:
Analysis of prolactin-induced Stat5 phosphorylation in the cytoplasmic and
nuclear fractions of MCF7 cells following shRNA knockdown of PTP1B.
MCF7 cells were infected with lentiviral-delivered shRNA against PTP1B or a
non-target control, and fractionated lysates were evaluated over a 1-hour
time course following a short pulse of prolactin for changes in phosphoty-
rosine-Stat5 levels. Cytoplasmic fractions (C) and nuclear fractions (D) were
immunoprecipitated with anti-Stat5, immunoblotted for phosphotyrosine-
Stat5, stripped, and reprobed for total Stat5 levels. Arrows indicate time
when prolactin (Prl) was removed.
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Figure 4. Stat5-responsive luciferase promoter activity was enhanced by
PTP1B knockdown. T47D cells stably transfected with a Stat5-responsive
-casein luciferase reporter were treated with PTP1B or non-target control
shRNA and stimulated for 8 hours with 10 nmol/L prolactin. Luciferase
activity was measured and graphed as the mean of three experiments (SD).
Inset: Representative immunoblot confirming PTP1B knockdown.
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Figure 5. PTP1B knockdown resulted in hypersensitivity and hyperactiva-
tion of prolactin-induced phosphotyrosine-Stat5. T47D cells were infected
with lentiviral-delivered shRNA against PTP1B or a non-target control, serum
starved, and stimulated with different doses of prolactin. A: Whole cell lysates
were collected 20 minutes following prolactin stimulation and analyzed by
immunoblotting for phosphotyrosine-Stat5. B: Densitometry was performed
from immunoblots from three experiments, and dose-response curves and
EC50 values were calculated.
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shRNA did not have this effect (Figure 2B). These obser-
vations suggest that a significant portion of the negative
regulation of Stat5 tyrosine phosphorylation by PTP1B is
mediated by a mechanism that involves dephosphoryla-
tion of the Stat5 tyrosine kinase, Jak2. This result is con-
sistent with reports demonstrating that PTP1B interacts
with Jak2 in signaling induced by growth hormone,42,43
leptin,44–47 and interferon,48 although it is the first time
such a relationship has been observed in breast cancer
cells or in the setting of prolactin-Jak2-Stat5 signaling.
We also established selective knockdown of SHP1,
SHP2, and VHR using lentiviral delivery of shRNA (Figure
2C). However, knockdown of SHP1, SHP2, or VHR was
not associated with enhanced prolactin-induced Jak2
tyrosine phosphorylation (Figure 2, D and E) or Stat5
tyrosine phosphorylation (data not shown).
PTP1B Modulation of the Prolactin/Jak2/Stat5
Pathway Also Occurs in MCF7 Breast Cancer
Cells
To determine whether the role of PTP1B observed in the
T47D cell line was also detectable in other breast cancer
cell lines we investigated the effect of PTP1B knockdown
on phosphotyrosine-Stat5 in MCF7 cells. MCF7 cells rep-
resent another luminal breast cancer cell line with rela-
tively high levels of prolactin receptors but with generally
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Figure 6. Expression of phosphotyrosine-Stat5, PTP1B, and TC-PTP in clinical breast tissue specimens. Phosphotyrosine-Stat5, PTP1B, and TC-PTP expression
were detected by immunohistochemistry in a tissue array containing nonmalignant and malignant tissues. Expression of nuclear phosphotyrosine-Stat5 was
reduced in malignant tissue compared to nonmalignant tissue (A) while expression of cytoplasmic PTP1B (B) and nuclear TC-PTP (C) were higher in malignant
tissue. Vertical bars represent 95% confidence intervals. **P  0.001, ***P  0.001 (t-test). D: Representative sections stained for phosphotyrosine-Stat5 and PTP1B
of nonmalignant (example 1) and malignant (examples 2 and 3) breast.
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weaker prolactin-induced Stat5 signaling than T47D
cells. Successful knockdown of PTP1B protein levels was
confirmed by whole cell lysate immunoblot (Figure 3A).
For optimal detection of prolactin-induced Stat5 tyrosine
phosphorylation, we fractionated the cytoplasmic and
nuclear compartments and immunoprecipitated Stat5.
Confirmation of proper cellular fractionation into nuclear
and cytoplasmic components was verified by examining
the levels of the nuclear pore proteins lamin A/C and the
cytoplasmic endoplasmic reticulum transmembrane pro-
tein calnexin (Figure 3B). Subsequent immunoblotting
was consistent with the effects seen in T47D cells, with
increased and sustained Stat5 tyrosine phosphorylation
in the cytoplasmic (Figure 3C) and particularly the nu-
clear (Figure 3D) fractions. Further confirmation of PTP1B
knockdown resulting in increased Stat5 activation was
provided by the observation of elevated nuclear levels of
total Stat5 protein in PTP1B-depleted cells following pro-
lactin stimulation (Figure 3D, lower panel). The observa-
tions in MCF7 cells demonstrated that the ability of PTP1B
to modulate levels of Stat5 tyrosine phosphorylation was
not restricted to T47D cells.
Knockdown of PTP1B Increased Levels of Stat5
Responsive -Casein Promoter-Driven
Luciferase Activity
To determine whether the increased phosphotyrosine-
Stat5 levels associated with knockdown of PTP1B were
functional and biologically active we used a stably trans-
fected T47D cell line containing a Stat5-responsive -ca-
sein promoter luciferase construct.60 We exposed the
cells to lentivirus carrying either PTP1B shRNA or non-
target control shRNA, allowed 72 hours for protein knock-
down to occur, and stimulated the cells for 8 hours with
prolactin. The cells were then lysed, luciferase activity
measured, and specific knockdown confirmed by immu-
noblot (Figure 4). In response to PTP1B knockdown, both
basal (1.3-fold increase, P  0.03) and prolactin-driven
(increased from 2.5- to 4.0-fold, P  0.004) luciferase
activity showed statistically significant increases over the
non-target shRNA control treated cells (Figure 4).
PTP1B Knockdown Increased the Prolactin
Sensitivity of T47D Cells as Measured by
Activation of Phosphotyrosine-Stat5 in
Response to Low Doses of Prolactin
Our prior experiments demonstrated that disruption of
PTP1B in T47D cells and MCF7 cells resulted in en-
hanced phosphotyrosine-Stat5 signaling induced by a
high dose of prolactin. We therefore determined whether
PTP1B up-regulation in breast cancer might represent a
mechanism that reduces sensitivity of the Stat5 pathway
to prolactin by investigating the effect of PTP1B knock-
down on prolactin-induced Stat5 activation over a con-
centration range of prolactin. PTP1B-targeted shRNA-
treated T47D cells were stimulated for 15 minutes with
prolactin concentrations ranging from 0.1 to 100 nmol/L.
Lysates were harvested and immunoblotted for active
and total Stat5 (Figure 5A). Phosphotyrosine-Stat5 band
intensity was quantified by densitometry from three inde-
pendent experiments and dose-response curves were
constructed by plotting the mean of the experiments
(Figure 5B). Importantly, PTP1B knockdown resulted in a
significant shift in EC50 from 7.20 nmol/L to 2.50 nmol/L,
which represents a magnitude of approximately half of a
logarithm. Also, maximum signal strength in cells treated
with PTP1B shRNA was 13% greater than cells treated
with control shRNA, and the response at 3.2 nmol/L pro-
lactin was over fivefold higher in PTP1B-suppressed
cells. Therefore, these results support the notion that
dysregulation of PTP1B in breast cancer may significantly
compromise the ability of Stat5 to act as an intracellular
sensor of circulating prolactin, and provide a mechanism
to explain how the increase of PTP1B activity could di-
minish normal phosphotyrosine-Stat5 signaling in inva-
sive breast cancer.
Expression of the Tyrosine Phosphatase PTP1B
but Not TC-PTP Is Negatively Correlated with
Nuclear Localized Phosphotyrosine-Stat5 in
Clinical Breast Cancer Specimens
Based on our observations in cell lines demonstrating
that PTP1B serves as a negative regulator of Jak2-Stat5
activation in breast cancer, we performed immunohisto-
chemistry of phosphotyrosine-Stat5, PTP1B, and TC-PTP
in a CEMA tissue array that included 47 malignant and 48
nonmalignant human breast specimens (material I). The
slides were scored blindly by an independent pathologist
and the intensity of nuclear phosphotyrosine-Stat5, cyto-
plasmic PTP1B, and nuclear TC-PTP were recorded.
While positive Stat5 status was reduced in invasive can-
cer (Figure 6A), PTP1B (Figure 6B) and TC-PTP (Figure
6C) expression levels were frequently increased in ma-
lignant compared to nonmalignant breast tissue (Table
1). The results of our analyses in carcinoma tissues with
evaluable staining showed that the intensity of nuclear
phosphotyrosine-Stat5 staining was negatively correlated
with cytoplasmic PTP1B staining (  0.38, P  0.02,
n  37) but not nuclear TC-PTP (  0.11, P  0.50, n 
39). However, no correlation between phosphotyrosine-
Table 1. Expression of Nuclear Phosphotyrosine-Stat5,
Cytoplasmic PTP1B, and Nuclear TC-PTP in
Nonmalignant and Malignant Breast Tissue of
Material I
Negative Positive Total
Nuclear phosphotyrosine-Stat5,
n (%)
Nonmalignant 17 (38%) 28 (62%) 45
Malignant 33 (73%) 12 (27%) 45
Cytoplasmic PTP1B, n (%)
Nonmalignant 28 (87%) 4 (13%) 32
Malignant 19 (45%) 23 (55%) 42
Nuclear TC-PTP, n (%)
Nonmalignant 25 (78%) 7 (22%) 32
Malignant 25 (57%) 19 (43%) 44
PTP1B Control of Stat5 in Breast Cancer 2979
AJP December 2010, Vol. 177, No. 6
Stat5 and PTP1B was seen in the nonmalignant tissues
(  0.01, P  0.94, n  31) or between phosphoty-
rosine-Stat5 and TC-PTP (  0.25, P  0.18, n  31).
Figure 6D shows representative sections of phosphoty-
rosine-Stat5 and PTP1B staining in nonmalignant breast
tissue (upper panels) and malignant breast tissues (mid-
dle and lower panels), reflecting low PTP1B expression in
tissues with high phosphotyrosine-Stat5 expression and
high PTP1B expression in tissues with low phosphoty-
rosine-Stat5 expression. Importantly, when stratified into
ER-positive and ER-negative breast cancer, the negative
correlation was observed in the ER-negative population
(  0.65, P  0.03, n  11) but not in the ER-positive
population (  0.22, P  0.37, n  19).
To further evaluate the relationship between PTP1B
and phosphotyrosine-Stat5 expression in human breast
cancer, a second material (material II) was investigated
using fluorescent immunostaining and quantitation by
AQUA. To quantitatively validate specificity of immuno-
staining for PTP1B, T47D cells were treated with increas-
ing amounts of PTP1B shRNA and analyzed for PTP1B
expression in formalin-fixed, paraffin-embedded cell pel-
lets by immunofluorescence. AQUA quantification re-
vealed dose-dependent reduced PTP1B expression rel-
ative to amount of PTP1B shRNA (Figure 7A). AQUA was
then used to correlate expression of PTP1B and phos-
photyrosine-Stat5 from a second CEMA tissue array con-
taining 100 invasive breast cancer specimens (grades
1–3). Representative immunofluorescent images of cyto-
plasmic PTP1B detection and nuclear phosphotyrosine-
Stat5 detection from two invasive breast carcinomas are
shown in Figure 7B. Consistent with the diaminobenzi-
dine immunohistochemistry data of material I, a strong
negative correlation was observed between levels of nu-
clear-localized phosphotyrosine-Stat5 and levels of cyto-
plasmic PTP1B within ER-negative invasive ductal carci-
nomas (Figure 7, B and C;   0.47, P  0.04, n  20)
and not in ER-positive cases ( 0.15, P 0.43, n 30).
Discussion
The present study is the first to implicate tyrosine phos-
phatase PTP1B as a major negative modulator of prolac-
tin-stimulated Stat5 tyrosine phosphorylation in human
breast cancer cell lines based on several lines of evi-
dence. First, we observed prolonged elevation tyrosine
phosphorylated Stat5 in prolactin-responsive breast can-
cer cell lines following knockdown of PTB1B using two
independent shRNAs but not following knockdown of
other candidate phosphatases that have been implicated
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Figure 7. PTP1B expression increases with histological grade and is in-
versely correlated with nuclear phosphotyrosine Stat5 expression. PTP1B
and phosphotyrosine-Stat5 expression were analyzed by immunofluorescent
staining and quantified by AQUA on a CEMA tissue array representing 100
invasive breast carcinoma specimens (grades 1–3). A: Validation of PTP1B
immunofluorescent staining and detection by AQUA demonstrated a dy-
namic range of PTP1B protein expression levels in T47D cells treated with
increasing amounts of PTP1B shRNA. B: Representative sections of the CEMA
tissue microarray stained for phosphotyrosine-Stat5 and PTP1B. C: Scatter
plot of phosphotyrosine-Stat5 intensity and PTP1B intensity in ER-negative
invasive ductal carcinoma patients.
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in Stat5 modulation in other cell types, including TC-PTP
modulation of prolactin-induced Stat5 phosphorylation in
Cos7 and COMMA-1D murine mammary epithelial
cells.39 Conversely, overexpression of PTP1B diminished
prolactin-induced Stat5 tyrosine phosphorylation. Sec-
ond, there was hyperresponsiveness and increased sen-
sitivity of Stat5 to extracellular prolactin stimulation in
T47D cells deficient in PTP1B, providing a mechanism to
explain how up-regulation of PTP1B frequently observed
in breast cancer could compromise Stat5 activation in
breast cancer. Last, a negative correlation was detected
between expression of PTP1B and levels of nuclear lo-
calized, tyrosine phosphorylated Stat5 in two indepen-
dent clinical breast cancer materials. Furthermore, we
determined based on PTP1B gene knockdown in T47D
human breast cancer cells that PTP1B negatively regu-
lates phosphorylation of the upstream Stat5 kinase, Jak2.
The stimulatory effect of PTP1B knockdown on prolac-
tin-induced tyrosine phosphorylation of Stat5 in breast
cancer cells was matched by a comparable effect on
levels of tyrosine phosphorylated Jak2, the upstream
Stat5 tyrosine kinase. Based on this observation, a ma-
jority of the suppressive effect of PTP1B on Stat5 tyrosine
phosphorylation in breast cancer cells may involve
PTP1B-mediated inactivation of Jak2, an observation
consistent with a growing body of related evidence from
studies of cytokine receptor signaling in non-mammary
model systems such as the growth hormone,42,43 lep-
tin,44–47 and interferon48 pathways, but unexpected in
light of previous observations of prolactin-mediated Jak2-
Stat5 signaling in non-breast cancer cells.40 In addition,
PTP1B has a 70-fold preference for tandem phosphoty-
rosines in the motif (E/D)-phosphotyrosine-phosphoty-
rosine-(R/K), a sequence found in the activation loop of
Jak2, over mono-phosphotyrosine sites such as the acti-
vating tyrosine on Stat5.63 While we cannot rule out that
PTP1B may also directly dephosphorylate Stat5 in breast
cells, our evidence best supports a model of PTP1B
regulating prolactin-activated Jak2 directly with the ef-
fects on phosphotyrosine-Stat5 secondary to modulation
of Jak2 kinase activity. Importantly, the present report
implicates PTP1B as a regulator of prolactin-mediated
Jak2 and Stat5 phosphorylation in human breast cancer,
providing a mechanism to explain the observed loss of
Stat5 activation in a significant portion of progressing
breast cancer.8
PTP1B has been reported to be up-regulated in human
breast cancer, a finding that correlated with aggressive
morphological characteristics,64 but until now no connec-
tion had been made between PTP1B and compromised
Stat5 activation. Interestingly, the negative correlation be-
tween levels of PTP1B and tyrosine phosphorylated Stat5
was most consistent in ER-negative breast cancer. Fur-
thermore, PTP1B is a known mediator of downstream
HER2 signaling via Src and ERK,65,66 and PTP1B expres-
sion is increased in cells lines that were transformed by
HER2,67,68 raising the possibility that PTP1B could also
serve as a mediator for inhibitory cross talk between the
HER2 and Stat5 pathway. However, such a relationship
remains to be investigated in larger materials. Studies of
spontaneous mammary carcinomas in mice have dem-
onstrated a potentially critical role for PTP1B in metastatic
progression. In the NDL2 mouse model, genetic loss or
pharmacological inhibition of PTP1B decreased lung me-
tastases.69 A potential function of PTP1B in breast cancer
progression was recently suggested based on observa-
tions that PTP1B modulated c-Src activity and further
implicated PTP1B in the regulation of invadopodia forma-
tion and breast cancer invasion.70 Although PTP1B may
regulate breast cancer invasiveness by multiple mecha-
nisms, inhibition of prodifferentiative and invasion-sup-
pressive effects of the Stat5 pathway12 could be an im-
portant factor not previously considered. A separate
study showed homozygous deletion of PTP1B in another
HER2-driven system, the MMTV-NeuNT mouse, delayed
or prevented mammary tumorigenesis altogether.71 How-
ever, analysis of several important signaling molecules in
the MMTV-NeuNT model identified decreased Erk activa-
tion in the preneoplastic glands as a possible contributor
to the PTP1B phenotype but noted no changes in the
phosphorylation of AKT, SRC, FAK, or Stat5 in either
preneoplastic glands or tumor lysates.
This report investigated whether disruption of normal
phosphatase expression could provide a mechanism to
explain how phosphotyrosine-Stat5 is lost during breast
cancer progression. We described how knockdown of
PTP1B resulted in increased levels of phosphotyrosine-
Jak2, the upstream activating kinase of Stat5, and
subsequently phosphotyrosine-Stat5 itself. Furthermore,
inhibition of normal PTP1B expression resulted in hyper-
sensitive and hyperactive Stat5 in response to low levels
of prolactin stimulation providing a mechanistic link be-
tween expression levels of a regulatory tyrosine phospha-
tase and signal transduction through the prolactin/Jak2/
Stat5 pathway. Ultimately, our biochemical, biological,
and mechanistic data were consistent with immunohisto-
chemical analyses of clinical breast cancer specimens,
which revealed a significant negative correlation between
PTP1B expression and the level of nuclear phosphoty-
rosine-Stat5. In summary, up-regulation of PTP1B activity
could represent an important mechanism behind the fre-
quently diminished Stat5 activation in breast cancer.
While other mechanisms may also be responsible for
decreased Stat5 tyrosine phosphorylation, phosphatases
represent intriguing druggable targets that could lead to
new strategies for breast cancer therapy.
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